{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:50:41Z","timestamp":1790128241843,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.106029","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:26:37Z","timestamp":1767360397000},"page":"106029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":false,"given":"U.","family":"Malapelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0016-6550","authenticated-orcid":false,"given":"F.","family":"Nasirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5532-4231","authenticated-orcid":false,"given":"A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Salomonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-A.","family":"Raiber-Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-9943","authenticated-orcid":false,"given":"Y.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.106029_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106029_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106029_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106029_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.21037\/tlcr-20-515","article-title":"Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment\u2014a narrative review","volume":"10","author":"Calvo","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"30","key":"10.1016\/j.esmoop.2025.106029_bib6","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.106029_bib7","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106029_bib8","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.3390\/cancers15112917","article-title":"New actions on actionable mutations in lung cancers","volume":"15","author":"Le","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106029_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"issue":"7511","key":"10.1016\/j.esmoop.2025.106029_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.106029_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"5676","key":"10.1016\/j.esmoop.2025.106029_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106029_bib14","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106029_bib15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106029_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106029_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106029_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106029_bib20","article-title":"EGFR testing patterns and detection of EGFR exon 20 insertions in the United States","volume":"3","author":"Lin","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"13","key":"10.1016\/j.esmoop.2025.106029_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310803","article-title":"Liquid biopsy in NSCLC: an investigation with multiple clinical implications","volume":"24","author":"Bertoli","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106029_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000492710","article-title":"Liquid biopsy and lung cancer","volume":"63","author":"Pisapia","year":"2019","journal-title":"Acta Cytol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106029_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.6004\/jadpro.2022.13.8.5","article-title":"Liquid biopsy for guiding treatment decisions in advanced non-small cell lung cancer","volume":"13","author":"Suk","year":"2022","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106029_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/tlcr-22-742","article-title":"Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review","volume":"12","author":"Tomasik","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106029_bib25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.106029_bib26","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106029_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4149\/neo_2018_181130N910","article-title":"Efficacy comparison of targeted next-generation sequencing in the identification of somatic mutations in circulating tumor DNA from different stages of lung cancer","volume":"66","author":"Chen","year":"2019","journal-title":"Neoplasma"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2019.10.013","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I-IV non-small cell lung cancer","volume":"22","author":"Jiang","year":"2020","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.esmoop.2025.106029_bib29","author":"Ma"},{"key":"10.1016\/j.esmoop.2025.106029_bib30","author":"Birnbaum"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/curroncol32020057","article-title":"Clinical utility of liquid biopsy for the early diagnosis of EGFR-mutant advanced lung cancer patients in a real-life setting (CLEAR Study)","volume":"32","author":"Samaha","year":"2025","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106029_bib32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamaoncol.2016.0173","article-title":"Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106029_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-024-05828-w","article-title":"\u2018Plasma first\u2019 approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma","volume":"150","author":"Rathor","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106029_bib35","doi-asserted-by":"crossref","first-page":"i38","DOI":"10.1093\/annonc\/mdx706","article-title":"Are liquid biopsies a surrogate for tissue EGFR testing?","volume":"29","author":"Goldman","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.106029_bib36","doi-asserted-by":"crossref","first-page":"S1052","DOI":"10.1016\/j.annonc.2025.08.2443","article-title":"1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC","volume":"36","author":"Arriola Aperribay","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106029_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106029_bib38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"224","key":"10.1016\/j.esmoop.2025.106029_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106029_bib40","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: an overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106029_bib41","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2017.8","article-title":"Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients","volume":"116","author":"Malapelle","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106029_bib42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jmoldx.2024.01.005","article-title":"Next-generation sequencing trends among adult patients with select advanced tumor types: a real-world evidence evaluation","volume":"26","author":"Ferreira-Gonzalez","year":"2024","journal-title":"J Mol Diagn"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106029_bib43","doi-asserted-by":"crossref","first-page":"e1774","DOI":"10.1200\/OP.20.01023","article-title":"Association between Medicare\u2019s national coverage determination and utilization of next-generation sequencing","volume":"17","author":"Sheinson","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106029_bib44","article-title":"Biomarker testing for patients with advanced\/metastatic nonsquamous NSCLC in the United States of America, 2015 to 2021","volume":"3","author":"Hess","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106029_bib45","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2021.05.006","article-title":"Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists","volume":"22","author":"Waterhouse","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2025.106029_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106029_bib47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cllc.2023.03.002","article-title":"Real-world biomarker testing patterns in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in a US community-based oncology practice setting","volume":"24","author":"Sireci","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106029_bib48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106029_bib49","first-page":"87","article-title":"Evidence based emergency medicine part 2: positive and negative predictive values of diagnostic tests","volume":"3","author":"Safari","year":"2015","journal-title":"Emerg (Tehran)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501899X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501899X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:55:21Z","timestamp":1773960921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292501899X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S205970292501899X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106029","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106029"}}